articleThe Lancet OncologyFeb 16, 2012GREEN OA

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Instituto de Biomedicina de Sevilla · Carlo Forlanini Hospital · +12 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

613
total citations
FWCI
63.89
Percentile
100%
References
35
Citations per year

Authors

17

Topics & keywords

Keywords
  • Pemetrexed
  • Medicine
  • Internal medicine
  • Oncology
  • Lung cancer
  • Clinical endpoint
  • Maintenance therapy
  • Performance status
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding